| Literature DB >> 28832247 |
Jisce R Puik1,2, Laura L Meijer1,2, Tessa Ys Le Large1,2,3, Mireia Mato Prado4, Adam E Frampton4, Geert Kazemier1, Elisa Giovannetti2,5.
Abstract
Cholangiocarcinoma (CCA) is a lethal malignancy originating from the biliary tract epithelium. Most patients are diagnosed at an advanced stage. Even after resection with curative intent, prognosis remains poor. Previous studies have reported the evolving role of miRNAs as novel biomarkers in cancer diagnosis, prognostication and chemotherapy response. Various miRNAs, such as miR-21, miR-26, miR-122 and miR-150, have been identified as possible blood-based biomarkers for noninvasive diagnosis of CCA. Moreover, epithelial-mesenchymal transition (EMT)- and angiogenesis-associated miRNAs have been implicated in tumor cell dissemination and are able to determine clinical outcome. In fact, miRNAs involved in cell survival might even determine chemotherapy response. This review provides an overview of known miRNAs as CCA-specific biomarkers.Entities:
Keywords: bile duct cancer; cholangiocarcinoma; diagnosis; liquid biopsy; miRNA; prediction; prognosis
Mesh:
Substances:
Year: 2017 PMID: 28832247 DOI: 10.2217/pgs-2017-0010
Source DB: PubMed Journal: Pharmacogenomics ISSN: 1462-2416 Impact factor: 2.533